

Application No.: 10/424,473

#### CLAIM AMENDMENTS

1. (original) A method to stimulate the immune system in vitro with an antigen in a formulation without interfering with the current preprogrammed response of the immune system to that antigen by means of administering the antigen in an otherwise immunoneutral formulation.
2. (original) A method to modulate an undesired current status of the immune system in an individual by:
  - a) evaluating the current immune response to an antigen in vitro according to the method of claim 1.
  - b) deciding on a therapeutic formulation suitable for specific immunomodulation away from of the individual's current unwanted immune response.
3. (withdrawn) A formulation that is immunoneutral to the immune system of an individual and capable of solubilizing hydrophobic antigen.
4. (withdrawn) A formulation according to claim 3 where immunoneutral hydrophobic solvent is specifies specific Serum Albumin.
5. (withdrawn) A formulation according to claim 4 including an antigen for stimulation of the immune system.
6. (withdrawn) A formulation for antigen specific downregulation of inflammatory responses comprising at least two of the ingredients antigen and alum.
7. (withdrawn) A formulation according to claim 5 or 6, where the antigen is of at least one from the group of ICA512 (IA2), ICA512B (IA2B), insulin, insulin B-chain, proinsulin, Hsp60, Hsp65, P277, ICA69, Glima38, GAD 65, GAD67, SOX13, Imogen 38,

Application No. 10/806,358

Sulfatide, MBP, MOG, Collagen II, 21-OHase, TPO, allergens, transplant antigens, cancer antigens, or parts, peptides or altered peptide ligands thereof.

8. (withdrawn) A kit for evaluation of lymphocyte reaction to antigen comprising a formulation according to claim 7.
9. (withdrawn) A therapeutic comprising a formulation according to claim 7.
10. (withdrawn) A therapeutic according to claim 9 where concentrations of antigen for in vitro stimulation typically is between 1-100 micrograms per ml.
11. (withdrawn) A therapeutic according to claim 9 where concentrations of antigen for in vitro stimulation typically is between 5-40 micrograms per ml.
12. (withdrawn) A therapeutic according to claim 9 where the subcutaneous administration of antigen for in vivo stimulation typically is between 0.1 micrograms per ml.
13. (withdrawn) A therapeutic according to claim 9 where intravenous administration of antigen for in vivo stimulation typically is between 0.1-5 mgs/kg.
14. (withdrawn) A method to stimulate the immune system in vitro with an antigen in a formulation without interfering with the current preprogrammed response of the immune system to that antigen by means of administering the antigen in an otherwise immunoneutral formulation.
15. (withdrawn) A method to modulate an undesired current status of the immune system in an individual by:
  - a) evaluating the current immune response to an antigen in vitro according to the method of claim 1.

Application No. 10/806,358

- b) deciding on a therapeutic formulation suitable for specific immunomodulation away from of the individual's current unwanted immune response.
16. (withdrawn) A formulation that is immunoneutral to the immune system of an individual and capable of solubilizing hydrophobic antigens.
17. (withdrawn) A formulation according to claim 3 where immunoneutral hydrophobic solvent is species specific Serum Albumin.
18. (withdrawn) A formulation according to claim 4 including an antigen for stimulation of the immune system.
19. (withdrawn) A formulation for antigen specific downregulation of inflammatory responses comprising at least two of the ingredients antigen and alum.
20. (withdrawn) A formulation according to claim 5 or 6, where the antigen is of at least one from the group of ICA512 (IA2), ICA512B (IA2B), insulin, insulin B-chain, proinsulin, Hsp60, Hsp65, P277, ICA69, Glma38, GAD 65, GAD67, SOX13, Imogen 38, Sulfatide, MBP, MOG, Collagen II, 21-Ohase, TPO, allergens, transplant antigens, cancer antigens, or parts, peptides or altered peptide ligands thereof.
21. (withdrawn) A kit for evaluation of lymphocyte reaction to antigen comprising a formulation according to claim 7.
22. (withdrawn) A therapeutic comprising a formulation according to claim 7.
23. (withdrawn) A therapeutic according to claim 9 where concentrations of antigen for in vitro stimulation typically is between 1-100 micrograms per ml.
24. (withdrawn) A therapeutic according to claim 9 where concentrations of antigen for in vitro stimulation typically is between 5-40 micrograms per ml.

Application No. 10/806,358

25. (withdrawn) A therapeutic according to claim 9 where the subcutaneous administration of antigen for in vivo stimulation typically is between 0.1 micrograms per ml.
26. (withdrawn) A therapeutic according to claim 9 where intravenous administration of antigen for in vivo stimulation typically is between 0.1-5 mgs/kg.